Seeking Alpha

InVivo plunges again as company updates scaffolding clinical plan

Shares of InVivo Therapeutics (NVIV.OB -22.3%) plummet for the second time in three sessions.

NVIV said today that "based on the judgement of new management," the first patient for a clinical trial of the company's biopolymer scaffolding is now expected to be enrolled in Q1 2014. NVIV also said it expects enrollment to take at least 21 months.

In May, the company said it expected to "commence the study in mid-2013 and submit data to the FDA by the end of 2014."

There's also chatter from SA contributor Biotech Sage (whose article looks to have been the impetus behind Friday's plunge) that "all video and TV appearances of [former CEO] Reynolds were removed" from the company's IR page.

SA contributor and Zacks analyst Jason Napodano is skeptical of an Aegis note which purportedly defends the shares: "Wow, Aegis out with a note saying, 'NVIV news is only slight delay' ... I don't consider 5-6 years a 'slight delay.'"

On the bright side, SA contributor Nancy Zhang is out with a more bullish take on the shares.

Comments (2)
  • Esekla
    , contributor
    Comments (4084) | Send Message
    Anyone who thought this was less than 5 yrs away from commercialization was just kidding themselves. I warned about this in article comments, as the stock was making a run above $5. This is the first sign that company is being realistically managed, rather than promoted, and thus readied for uplisting.


    Tweets this morning on this from Napodano were rather negative, but now in his most recent article, he concedes the points above.


    I go by the same name on Twitter.
    27 Aug 2013, 11:40 AM Reply Like
  • Derek2012
    , contributor
    Comments (27) | Send Message
    It's a bloodbath
    27 Aug 2013, 12:37 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs